Target Price | $54.57 |
Price | $28.44 |
Potential |
91.88%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Agios Pharmaceuticals, Inc. 2026 .
The average Agios Pharmaceuticals, Inc. target price is $54.57.
This is
91.88%
register free of charge
$74.00
160.20%
register free of charge
$43.00
51.20%
register free of charge
|
|
A rating was issued by 9 analysts: 6 Analysts recommend Agios Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Agios Pharmaceuticals, Inc. stock has an average upside potential 2026 of
91.88%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 36.50 | 51.16 |
36.09% | 40.15% | |
EBITDA Margin | -1,150.90% | -957.99% |
19.80% | 16.76% | |
Net Margin | 1,822.86% | -839.58% |
235.12% | 146.06% |
9 Analysts have issued a sales forecast Agios Pharmaceuticals, Inc. 2025 . The average Agios Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Agios Pharmaceuticals, Inc. EBITDA forecast 2025. The average Agios Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Agios Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Agios Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 11.64 | -7.51 |
283.89% | 164.52% | |
P/E | negative | |
EV/Sales | 15.50 |
5 Analysts have issued a Agios Pharmaceuticals, Inc. forecast for earnings per share. The average Agios Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Agios Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 18 2024 |
RBC Capital |
Locked
➜
Locked
|
Locked | Dec 10 2024 |
Scotiabank |
Locked
➜
Locked
|
Locked | Dec 09 2024 |
RBC Capital |
Locked
➜
Locked
|
Locked | Nov 01 2024 |
Scotiabank |
Locked
➜
Locked
|
Locked | Nov 01 2024 |
Scotiabank |
Locked
➜
Locked
|
Locked | Oct 16 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 18 2024 |
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 10 2024 |
Locked
Scotiabank:
Locked
➜
Locked
|
Dec 09 2024 |
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 01 2024 |
Locked
Scotiabank:
Locked
➜
Locked
|
Nov 01 2024 |
Locked
Scotiabank:
Locked
➜
Locked
|
Oct 16 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.